Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

MaxCyte (MXCT)

Price 342.50p on 29-03-2024 at 04:45:10
Change 0.00p 0%
Buy 350.00p
Sell 335.00p
Buy / Sell MXCT Shares
Last Trade: Unknown 200.00 at 334.53296p
Day's Volume: 0
Last Close: 342.50p
Open: 0.00p
ISIN: US57777K1060
Day's Range 0.00p - 0.00p
52wk Range: 172.50p - 430.00p
Market Capitalisation: £357m
VWAP: 0.00p
Shares in Issue: 104m

Recent Trades History MaxCyte (MXCT)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 200 334.53296p Currency Conversion
OTC Trade
19:00:09 - 28-Mar-24
Sell* 1,500 340.00p Ordinary
16:18:24 - 28-Mar-24
Sell* 1,500 340.00p Ordinary
16:18:03 - 28-Mar-24
Sell* 1,500 340.00p Ordinary
16:17:54 - 28-Mar-24
Sell* 487 340.00p Ordinary
16:15:23 - 28-Mar-24
Unknown* 200 340.86732p Currency Conversion
OTC Trade
14:54:15 - 28-Mar-24
Unknown* 650 341.10486p Currency Conversion
OTC Trade
14:54:15 - 28-Mar-24
Unknown* 200 341.10486p Currency Conversion
OTC Trade
14:54:15 - 28-Mar-24
Buy* 6 350.00p SI Trade
14:51:05 - 28-Mar-24
Sell* 1,516 341.00p Ordinary
13:35:27 - 28-Mar-24

Share Price History for MaxCyte

Time period:
to
Date Open High Low Close Volume

Share News for MaxCyte

IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25%

13th Mar 2024 11:54

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Net loss widens to USD37.9 million in 2023 from USD23.6 million in 2022, as revenue declines by 6.7% to USD41.3 million from 44.3 million. Core business revenue falls by 25% to USD29.8 million from USD39.6 million, but strategic platform license programme-related revenue more than doubles to USD11.5 million from USD4.6 million. In the fourth quarter alone, revenue is USD15.7 million, up 26% from USD12.4 million a year before, as core business revenue falls by 32% but SPL revenue more than quadruples. Read More

EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit

5th Mar 2024 20:43

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

UK earnings, trading statements calendar - next 7 days

5th Mar 2024 16:06

Read More

IN BRIEF: MaxCyte signs licencing deal with cell therapy company Wugen

30th Jan 2024 13:58

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Signs strategic platform licence with Wugen Inc, a US-based clinical-stage biotech company developing off-the-shelf cell therapies for the treatment of hematological and solid cancer tumour malignancies. Wugen's lead program is evaluating WU-CART-007, a cell therapy for the treatment of relapsed or refractory T-cell acute lymphoblastic leukaemia. Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte's unique Flow electroporation technology and its trademarked ExPERT research platform. In exchange, MaxCyte will receive annual licence fees and programme-related revenue, although precise transaction details were not provided. Read More

IN BRIEF: MaxCyte chief scientific officer leaves firm

29th Jan 2024 17:56

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Announces departure of Cenk Sumen as chief scientific officer, but he will remain on advisory board. Read More

FTSE 100 Latest
Value7,952.62
Change0.00

Login to your account

Forgot Password?

Not Registered